US Stock MarketDetailed Quotes
LABP Landos Biopharma
- 22.2050
- -0.1250-0.56%
Close May 13 16:00 ET
69.41MMarket Cap-5551P/E (TTM)
22.4200High22.1300Low3.90KVolume22.4100Open22.3300Pre Close86.65KTurnover0.29%Turnover RatioLossP/E (Static)3.13MShares22.840052wk High3.00P/B29.53MFloat Cap2.500052wk Low--Dividend TTM1.33MShs Float169.8900Historical High--Div YieldTTM1.30%Amplitude2.1110Historical Low22.2410Avg Price1Lot Size
About Landos Biopharma Company
Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of novel, oral, once-daily therapeutics for patients with certain immunology diseases. It offers NX-13, a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway. The firm's preclinical candidates include LABP-73, LABP-66, and LABP-69. The company was founded by Josep Bassaganya-Riera in January 2017 and is headquartered in Blacksburg, VA.
Company Profile
SymbolLABP
Company NameLandos Biopharma
Listing DateFeb 4, 2021
Issue Price16.00
Founded2017
CEOMr. Gregory Oakes
MarketNASDAQ
Employees19
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address1800 Kraft Drive,Suite 216
CityBlacksburg
ProvinceVirginia
CountryUnited States of America
Zip Code24060
Phone1-540-218-2232
Company Executives
- Name
- Position
- Salary
- Gregory Oakes
- Director, Chief Executive Officer and Principal Financial Officer
- 1.76M
- Fabio Cataldi
- Executive Vice President and Chief Medical Officer
- 477.60K
- Christopher Nishan Garabedian
- Chairman of the Board
- 103.99K
- Alka Batycky
- Director
- --
- Roger Adsett
- Independent Director
- 91.89K
- Tiago M. Girao
- Independent Director
- 91.49K
- Timothy M. Mayleben
- Independent Director
- 565.90K
- Frederick C. Callori
- Independent Director
- 93.99K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg